We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exiqon Releases Second Generation Human and Mouse microRNA Inhibitor Libraries
Product News

Exiqon Releases Second Generation Human and Mouse microRNA Inhibitor Libraries

Exiqon Releases Second Generation Human and Mouse microRNA Inhibitor Libraries
Product News

Exiqon Releases Second Generation Human and Mouse microRNA Inhibitor Libraries


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Exiqon Releases Second Generation Human and Mouse microRNA Inhibitor Libraries"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Exiqon A/S has announced the launch of the 2nd generation of miRCURY LNA™ microRNA Inhibitor libraries for genome-wide screening of microRNA function in human and mouse. Several libraries have already been shipped to the first customers.

The new human microRNA inhibitor library targets almost 1,000 different microRNAs which makes it the library with the highest coverage on the market. The human library also targets 40 proprietary miRPlus™ microRNAs. The new mouse library likewise has the highest coverage as it targets more than 700 microRNAs.

“By use of our proprietary LNA™ technology we have been able to design highly potent microRNA inhibitors with uniform and specific affinity for their targets which is critical for successful high throughput screenings”, said Vice President Sales & Marketing, Dr. Henrik M. Pfundheller and added: “Due to the high potency caused by the high affinity and biostability of the LNA™, the microRNA inhibitors may be applied at very low concentrations minimizing problems with secondary effects”.

Advertisement